General Hospital Psychiatry
Volume 27, Issue 2 , Pages 100-112 , March 2005

Correlates and consequences of chronic insomnia

Received 29 March 2004 ,Accepted 21 September 2004.

References 

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-text revision. 4th ed.. Washington (DC): American Psychiatric Publishing Inc.; 2000;
  2. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch. Gen. Psychiatry. 1985;42(3):225–232
  3. McCall WV. A psychiatric perspective on insomnia. J. Clin. Psychiatry. 2001;62(Suppl. 10):27–32
  4. Brunello N, Armitage R, Feinberg I, et al. Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment. Neuropsychobiology. 2000;42(3):107–119
  5. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am. J. Psychiatry. 1990;147(9):1189–1194
  6. Shochat T, Loredo J, Ancoli-Israel S. Sleep disorders in the elderly. Curr. Treat. Options Neurol. 2001;3(1):19–36
  7. Thase ME, Simons AD, Reynolds CF. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive behavior therapy. Arch. Gen. Psychiatry. 1996;53(2):99–108
  8. Agargun MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J. Clin. Psychiatry. 1997;58(6):249–251
  9. Nowlin-Finch NL, Altshuler LL, Szuba MP, Mintz J. Rapid resolution of first episodes of mania: sleep related?. J. Clin. Psychiatry. 1994;55(1):26–29
  10. Londborg PD, Smith WT, Glaudin V, Painter JR. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. J. Affect. Disord. 2000;61(1–2):73–79
  11. Buysse DJ, Reynolds CF, Kupfer DJ, et al. Clinical diagnoses in 216 insomnia patients using the International Classification of sleep disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV Field Trial. Sleep. 1994;17(7):630–637
  12. Roth T. New developments for treating sleep disorders. J. Clin. Psychiatry. 2001;62(Suppl. 10):3–4
  13. Shochat T, Umphress J, Israel AG, Ancoli-Israel S. Insomnia in primary care patients. Sleep. 1999;22(Suppl. 2):S359–S365
  14. Dorrepaal KL, Aaronson NK, van Dam FS. Pain experience and pain management among hospitalized cancer patients. A clinical study. Cancer. 1989;63(3):593–598
  15. Gislason T, Almqvist M. Somatic diseases and sleep complaints. An epidemiological study of 3201 Swedish men. Acta Med. Scand. 1987;221(5):475–481
  16. Benca RM. Consequences of insomnia and its therapies. J. Clin. Psychiatry. 2001;62(Suppl. 10):33–38
  17. McCrae CS, Lichstein KL. Managing insomnia in long-term care. Annals Long-Term Care. 2002;10:38–43
  18. Reite M, Ruddy J, Nagel K. Concise guide to evaluation and management of sleep disorders. Washington (DC): American Psychiatric Press; 1997;
  19. Buysse DJ, Reynolds CF, Hauri PJ, et al. Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trial. Am. J. Psychiatry. 1994;151(9):1351–1360
  20. Ohayon MM. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J. Psychiatr. Res. 1997;31(3):333–346
  21. Gagnon LM, Patten SB. Major depression and its association with long-term medical conditions. Can. J. Psychiatry. 2002;47(2):149–152
  22. Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am. J. Psychiatry. 1988;145(8):976–981
  23. Patten SB. Long-term medical conditions and major depression in the Canadian population. Can. J. Psychiatry. 1999;44(2):151–157
  24. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch. Gen. Psychiatry. 2003;60(1):39–47
  25. Wilson KG, Eriksson MY, D'Eon JL, Mikail SF, Emery PC. Major depression and insomnia in chronic pain. Clin. J. Pain. 2002;18(2):77–83
  26. Sayar K, Arikan M, Yontem T. Sleep quality in chronic pain patients. Can. J. Psychiatry. 2002;47(9):844–848
  27. Riedinger MS, Dracup KA, Brecht ML. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. Am. J. Crit. Care. 2002;11(3):211–219
  28. Burg MM, Abrams D. Depression in chronic medical illness: the case of coronary heart disease. J. Clin. Psychol. 2001;57(11):1323–1337
  29. Krakow B, Melendrez D, Ferreira E, et al. Prevalence of insomnia symptoms in patients with sleep-disordered breathing. Chest. 2001;120(6):1923–1929
  30. Burn DJ. Depression in Parkinson's disease. Eur. J. Neurol. 2002;9(Suppl. 3):44–54
  31. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep. 1999;22(Suppl. 2):S354–S358
  32. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999;22(Suppl. 2):S347–S353
  33. Roth T. The relationship between psychiatric diseases and insomnia. Int. J. Clin. Pract. Suppl. 2001;(116):3–8
  34. National Sleep Foundation. Sleep in America: a national survey of US adults. Washington (DC): National Sleep Foundation; 1991;
  35. Haponik EF, Frye AW, Richards B, et al. Sleep history is neglected diagnostic information. Challenges for primary care physicians. J. Gen. Intern. Med. 1996;11(12):759–761
  36. Doghramji K. The need for flexibility in dosing of hypnotic agents. Sleep. 2000;23(Suppl. 1):S16–S20
  37. Liu X, Uchiyama M, Kim K, et al. Sleep loss and daytime sleepiness in the general adult population of Japan. Psychiatry Res. 2000;93(1):1–11
  38. Nugent AM, Gleadhill I, McCrum E, et al. Sleep complaints and risk factors for excessive daytime sleepiness in adult males in Northern Ireland. J. Sleep Res. 2001;10(1):69–74
  39. Ohayon MM, Zulley J. Correlates of global sleep dissatisfaction in the German population. Sleep. 2001;24(7):780–787
  40. National Sleep Foundation. 2002 Sleep in America Poll. Washington (DC): WB & A Market Research; 2002 (Apr.);
  41. Carskadon MA, Brown ED, Dement WC. Sleep fragmentation in the elderly: relationship to daytime sleep tendency. Neurobiol. Aging. 1982;3(4):321–327
  42. Insomnia: assessment and management in primary care. NIH Publication No. 98-4088. Washington, DC, 1998; (Sept.).
  43. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA. 1989;262(11):1479–1484
  44. Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MJ. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am. J. Epidemiol. 1997;146(2):105–114
  45. Livingston G, Blizard B, Mann A. Does sleep disturbance predict depression in elderly people? A study in inner London. Br. J. Gen. Pract. 1993;43:445–448
  46. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch. Intern. Med. 1998;158:1099–1107
  47. Radecki SE, Brunton SA. Management of insomnia in office-based practice. National prevalence and therapeutic patterns. Arch. Fam. Med. 1993;2(11):1129–1134
  48. Weyerer S, Dilling H. Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study. Sleep. 1991;14(5):392–398
  49. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology. 2001;44(3):139–149
  50. Arriaga F, Paiva T, Matos-Pires A, et al. The sleep of non-depressed patients with panic disorder: a comparison with normal controls. Acta Psychiatr. Scand. 1996;93(3):191–194
  51. Okuji Y, Matsuura M, Kawasaki N, et al. Prevalence of insomnia in various psychiatric diagnostic categories. Psychiatry Clin. Neurosci. 2002;56(3):239–240
  52. Neylan TC, Reynolds CF, Kupfer DJ. Sleep disorders. In:  Hales RE,  Yudofsky SC editor. Textbook of clinical psychiatry. Washington (DC): American Psychiatric Publishing; 2003;p. 975–1000
  53. Wooten VD, Buysse DJ. Sleep in psychiatric disorders. In:  Chokroverty S,  Daroff RB editor. Sleep disorders medicine: basic sciences, technical considerations, and clinical aspects. Boston (Mass): Butterworth-Heinemann Medical; 1999;p. 573–586
  54. Chokroverty S. Clinical companion to sleep disorders medicine. 2nd ed.. Boston (Mass): Butterworth-Heinemann; 2000;
  55. Doghramji PP. Detection of insomnia in primary care. J. Clin. Psychiatry. 2001;62(Suppl. 10):18–26
  56. Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric disorders. A meta-analysis. Arch. Gen. Psychiatry. 1992;49(8):651–668
  57. Erman MK. Sleep architecture and its relationship to insomnia. J. Clin. Psychiatry. 2001;62(Suppl. 10):9–17
  58. Szuba MP, Fernando AT, Groh-Szuba G. Sleep abnormalities in treatment-resistant mood disorders. In:  Amsterdam JD,  Nierenberg AA editor. Treatment resistant mood disorders. Cambridge (UK): Cambridge University Press; 2001;p. 96–110
  59. Reynolds CF. Sleep disorders. In:  Sadavoy J,  Lazarus LW,  Jarvik LF,  Grossberg GT editor. Comprehensive review of geriatric psychiatry-II. Washington (DC): American Psychiatric Press; 1996;p. 693–712
  60. Webb WB. Sleep in older persons: sleep structures of 50- to 60-year-old men and women. J. Gerontol. 1982;37(5):581–586
  61. McCall WV. Management of primary sleep disorders among elderly persons. Psychiatr. Serv. 1995;46(1):49–55
  62. Moe KE. Reproductive hormones, aging, and sleep. Semin. Reprod. Endocrinol. 1999;17(4):339–348
  63. Strang P. Emotional and social aspects of cancer pain. Acta Oncol. 1992;31(3):323–326
  64. Kramer M. The selective mood regulatory function of dreaming: an update and revision. In:  Moffitt AR,  Kramer M,  Hoffman RF editor. The function of dreaming. Albany: State University of New York Press; 1993;p. 139–195
  65. Nofzinger EA, Schwartz RM, Reynolds CF, Thase ME, Jennings RJ, Frank E, et al. Affect intensity and phasic REM sleep in depressed men before and after treatment with cognitive behavior therapy. J. Consult. Clin. Psychol. 1994;62:83–91
  66. Uhde TW. Anxiety disorders. In:  Kryger MH,  Roth T,  Dement WC editor. Principles and practice of sleep medicine. New York: WB Saunders; 2000;p. 1123–1139
  67. Benson KL, Zarcone VP. Schizophrenia. In:  Kryger MH,  Roth T,  Dement WC editor. Principles and practice of sleep medicine. New York: WB Saunders; 2000;p. 1159–1167
  68. Bourdet C, Goldenberg F. Insomnia in anxiety: sleep EEG changes. J. Psychosom. Res. 1994;38(Suppl. 1):93–104
  69. Wei S, Teitelbaum SL, Wang MW, Ross FP. Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors. Endocrinology. 2001;142(3):1290–1295
  70. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov. Disord. 1990;5(4):280–285
  71. Aldrich MS. Parkinsonism. In:  Kryger MH,  Roth T,  Dement WC editor. Principles and practice of sleep medicine. Philadelphia (Pa): WB Saunders; 2000;p. 1051–1057
  72. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am. J. Psychiatry. 1997;154(10):1417–1423
  73. Schwartz S, McDowell AW, Cole SR, et al. Insomnia and heart disease: a review of epidemiologic studies. J. Psychosom. Res. 1999;47(4):313–333
  74. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol. Psychiatry. 1996;39(6):411–418
  75. Walsh J, Ustun B. Prevalence and health consequences of insomnia. Sleep. 1999;22(Suppl. 3):S427–S436
  76. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia. An overview. Pharmacoeconomics. 1996;10(Suppl. 1):1–14
  77. Stoller MK. Economic effects of insomnia. Clin. Ther. 1994;16(5):873–897
  78. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness — 1991. Soc. Psychiatry Psychiatr. Epidemiol. 1995;30(5):213–219
  79. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum. 1995;38(10):1351–1362
  80. Dinges DF, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4–5 hours per night. Sleep. 1997;20(4):267
  81. Chevalier H, Los F, Boichut D, et al. Evaluation of severe insomnia in the general population: results of a European multinational survey. J. Psychopharmacol. 1999;13(4 Suppl. 1):S21–S24
  82. Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J. Am. Geriatr. Soc. 2001;49(9):1185–1189
  83. Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB. Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. Pharmacoeconomics. 1998;14(6):629–637
  84. Lichstein KL, Durrence HH, Bayen UJ, Riedel BW. Primary versus secondary insomnia in older adults: subjective sleep and daytime functioning. Psychol. Aging. 2001;16(2):264–271
  85. Poland RE, McCracken JT, Lutchmansingh P, Tondo L. Relationship between REM sleep latency and nocturnal cortisol concentrations in depressed patients. J. Sleep Res. 1992;1(1):54–57
  86. Giles DE, Schlesser MA, Rush AJ, et al. Polysomnographic findings and dexamethasone nonsuppression in unipolar depression: a replication and extension. Biol. Psychiatry. 1987;22(7):872–882
  87. Mendlewicz J, Kerkhofs M, Hoffmann G, Linkowski P. Dexamethasone suppression test and REM sleep in patients with major depressive disorder. Br. J. Psychiatry. 1984;145:383–388
  88. Rubinow DR, Post RM, Savard R, Gold PW. Cortisol hypersecretion and cognitive impairment in depression. Arch. Gen. Psychiatry. 1984;41(3):279–283
  89. Jimerson DC, Insel TR, Reus VI, Kopin IJ. Increased plasma MHPG in dexamethasone-resistant depressed patients. Arch. Gen. Psychiatry. 1983;40(2):173–176
  90. Horne JA. Human sleep, sleep loss and behaviour. Implications for the prefrontal cortex and psychiatric disorder. Br. J. Psychiatry. 1993;162:413–419
  91. Hartlage S, Alloy LB, Vazquez C, Dykman B. Automatic and effortful processing in depression. Psychol. Bull. 1993;113(2):247–278
  92. Chemerinski E, Ho BC, Flaum M, et al. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr. Psychiatry. 2002;43(5):393–396
  93. McCracken LM, Iverson GL. Disrupted sleep patterns and daily functioning in patients with chronic pain. Pain Res. Manag. 2002;7(2):75–79
  94. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J. Intern. Med. 2002;251(3):207–216
  95. Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6800 persons over three years. Sleep. 1999;22(Suppl. 2):S366–S372
  96. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J. Psychiatr. Res. 2003;37(1):9–15
  97. McCall WV. Sleep in the elderly: burden, diagnosis, and treatment. Prim. Care Companion J. Clin. Psychiat. 2004;6:9–20
  98. Levitan RD, Shen JH, Jindal R, et al. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. J. Psychiatry Neurosci. 2000;25(4):337–346
  99. Leger D, Quera-Salva MA, Philip P. Health-related quality of life in patients with insomnia treated with zopiclone. Pharmacoeconomics. 1996;10(Suppl. 1):39–44
  100. Walsh JK, Muehlbach MJ, Lauter SA, Hilliker NA, Schweitzer PK. Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. J. Rheumatol. 1996;23(2):245–252
  101. Smith MT, Neubauer DN. Cognitive behavior therapy for chronic insomnia. Clin. Cornerstone. 2003;5(3):28–40
  102. Edinger JD, Sampson WS. A primary care “friendly” cognitive behavioral insomnia therapy. Sleep. 2003;26:177–182
  103. Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am. J. Psychiatry. 2002;159(1):5–11
  104. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281:991–999
  105. Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol. Psychiatry. 1998;44(1):3–14
  106. Sharpley AL, Williamson DJ, Attenburrow ME, et al. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl.). 1996;126(1):50–54
  107. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol. Bull. 1996;32(4):637–646
  108. Nofzinger EA, Reynolds CF, Thase ME, et al. REM sleep enhancement by bupropion in depressed men. Am. J. Psychiatry. 1995;152(2):274–276
  109. Armitage R, Yonkers K, Cole D, Rush AJ. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J. Clin. Psychopharmacol. 1997;17(3):161–168
  110. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br. J. Psychiatry. 2002;180:528–535
  111. Neylan TC, Lenoci M, Maglione ML, et al. The effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. J. Clin. Psychiatry. 2003;64(4):445–450
  112. Winokur A, Sateia MJ, Hayes JB, et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol. Psychiatry. 2000;48(1):75–78
  113. Winokur A, DeMartinis NA, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J. Clin. Psychiatry. 2003;64(10):1224–1229
  114. Schittecatte M, Dumont F, Machowski R, et al. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology. 2002;46(4):197–201
  115. Preskorn SH. Antidepressant drug selection: criteria and options. J. Clin. Psychiatry. 1994;55(Suppl. A):6–22
  116. Thase ME, Nierenberg AA, Keller MB, Panagides J. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J. Clin. Psychiatry. 2001;62(10):782–788
  117. Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin. Neuropharmacol. 1997;20(2):116–125
  118. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum. Psychopharmacol. 1998;13:191–198
  119. Hajak G, Cluydts R, Declerck A, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int. Clin. Psychopharmacol. 2002;17(1):9–17
  120. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J. Clin. Psychiatry. 1994;55(5):192–199
  121. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int. J. Geriatr. Psychiatry. 2000;15(8):704–712
  122. Elie R, Ruther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J. Clin. Psychiatry. 1999;60(8):536–544
  123. Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int. Clin. Psychopharmacol. 2000;15(3):141–152
  124. Kales A, Manfredi RL, Vgontzas AN, et al. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin. Pharmacol. Ther. 1991;49(4):468–476
  125. Mitler MM, Seidel WF, van den HJ, Greenblatt DJ, Dement WC. Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. J. Clin. Psychopharmacol. 1984;4(1):2–13
  126. Roehrs T, Vogel G, Vogel F, et al. Dose effects of temazepam tablets on sleep. Drugs Exp. Clin. Res. 1986;12(8):693–699
  127. Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin. Neuropharmacol. 1996;19(4):333–340
  128. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J. Int. Med. Res. 1992;20(2):150–161
  129. Frattola L, Maggioni M, Cesana B, Priore P. Double blind comparison of zolpidem 20 mg versus flunitrazepam 2 mg in insomniac in-patients. Drugs Exp. Clin. Res. 1990;16(7):371–376
  130. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000;60(2):413–445
  131. Drake CL, Roehrs TA, Mangano RM, Roth T. Dose–response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. Hum. Psychopharm. 2000;15(8):595–604
  132. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem in SSRI-treated patients with persistent insomnia. J. Clin. Psychiatry. 1999;60(10):668–676
  133. Mitler MM, Carskadon MA, Phillips RL, et al. Hypnotic efficacy of temazepam: a long-term sleep laboratory evaluation. Br. J. Clin. Pharmacol. 1979;8(1):63S–68S
  134. Ngen CC, Hassan R. A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. Int. Clin. Psychopharmacol. 1990;5(3):165–171
  135. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J. Clin. Psychiatry. 1991;52(Suppl.):16–23
  136. Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J. Clin. Psychopharmacol. 1996;16(2):146–157
  137. Elie R, Lavoie G, Bourgouin J, Le Morvan P. Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int. Clin. Psychopharmacol. 1990;5(4):279–286
  138. O'Hair DE, Winsauer HJ. Evaluation of short-term treatment with 30 mg of quazepam in insomniac outpatients. Clin. Ther. 1981;4(4):291–301
  139. Walsh JK, Targum SD, Pegram V, et al. A multi-center clinical investigation of estazolam: short-term efficacy. Curr. Ther. Res. 1984;36:866–874
  140. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. CMAJ. 2000;162(2):216–220
  141. Bowen AJ. Comparative efficacy of triazolam, flurazepam and placebo in out-patients insomniacs. J. Int. Med. Res. 1978;6(4):337–342
  142. Vogel GW, Barker K, Gibbons P, Thurmond A. A comparison of the effects of flurazepam 30 mg and triazolam 0.5 mg on the sleep of insomniacs. Psychopharmacology (Berl.). 1976;47(1):81–86
  143. Fabre LF, McLendon DM, Harris RT. Preference studies of triazolam with standard hypnotics in out-patients with insomnia. J. Int. Med. Res. 1976;4(4):247–254
  144. Fleming JA, McClure DJ, Mayes C, Phillips R, Bourgouin J. A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int. Clin. Psychopharmacol. 1990;5(Suppl. 2):29–37
  145. Kales A. Benzodiazepine hypnotics and insomnia. Hosp. Pract. (Off. Ed.). 1990;25(Suppl. 3):7–21
  146. Roehrs T, Pedrosi B, Rosenthal L, Roth T. Hypnotic self administration and dose escalation. Psychopharmacology. 1996;127:150–154
  147. Roehrs T, Bonahoom A, Pedrosi B, Rosenthal L, Roth T. Treatment regimen and hypnotic self-administration. Psychopharmacology. 2001;155:11–17
  148. Kales A, Kales JD, Bixler EO, et al. Effectiveness of hypnotic drugs with prolonged use: flurazepam and pentobarbital. Clin. Pharmacol. Ther. 1975;18:356–363
  149. Walsh JK, Jamieson A, Schweitzer PK, et al. Intermittent use of zolpidem for the treatment of primary insomnia. Sleep. 2000;23:A86
  150. Maarek L. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J. Int. Med. Res. 1992;20:162–170
  151. Oswald I, French C, Adam K, Gilham J. Benzodiazepine hypnotics remain effective for 24 weeks. BMJ. 1982;284:860–863
  152. Mendelson WB, Roth T, Cassella J, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 new clinical drug evaluation unit meeting symposium. Sleep Med. Rev. 2004;8:7–17
  153. Busto U, Sellers EM, Naranjo CA, et al. Patterns of benzodiazepine abuse and dependence. Br. J. Addict. 1986;81:87–94
  154. Jaffe JH, Bloor R, Crome I, Carr M, Alam F, Simmons A, et al. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction. 2004;99(2):165–173
  155. IMS America. 2002; (March).
  156. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep. 1999;22(3):371–375
  157. Parrino L, Spaggiari MC, Boselli M, Di Giovanni G, Terzano MG. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology (Berl.). 1994;116(4):389–395
  158. Mouret J, Lemoine P, Minuit MP, Benkelfat C, Renardet M. Effects of trazodone on the sleep of depressed subjects — a polygraphic study. Psychopharmacology (Berl.). 1988;95(Suppl.):S37–S43
  159. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002;26(2):249–260
  160. van Bemmel AL, Havermans RG, van Diest R. Effects of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology (Berl.). 1992;107(4):569–574
  161. Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br. J. Clin. Pharmacol. 1983;16(2):139–144
  162. Blacker R, Shanks NJ, Chapman N, Davey A. The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. Psychopharmacology (Berl.). 1988;95(Suppl.):S18–S24
  163. Davey A. A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice. Psychopharmacology (Berl.). 1988;95(Suppl.):S25–S30
  164. Moon CA, Davey A. The efficacy and residual effects of trazodone (150 mg nocte) and mianserin in the treatment of depressed general practice patients. Psychopharmacology (Berl.). 1988;95(Suppl.):S7–S13
  165. Feighner JP, Boyer WF. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology (Berl.). 1988;95(Suppl.):S50–S53
  166. Allen RP, Mendels J, Nevins DB, Chernik DA, Hoddes E. Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months. J. Clin. Pharmacol. 1987;27(10):768–775
  167. Krystal A, Walsh J, Roth T, Amato DA, Wessel T. The sustained efficacy and safety of eszopiclone over six months of nightly treatment: a placebo-controlled study in patients with chronic insomnia. Sleep. 2003;26:A310
  168. Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med. 2000;1:41–49

PII: S0163-8343(04)00126-4

doi: 10.1016/j.genhosppsych.2004.09.006

General Hospital Psychiatry
Volume 27, Issue 2 , Pages 100-112 , March 2005

Article Tools